The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

AstraZeneca and Daiichi's first co-developed ... In December, Datroway was approved in Japan to treat patients with a type of breast cancer who had previously received chemotherapy.

Department of Trade and Industry Secretary Cristina Roque held a series of productive meetings with top executives of global ...

The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...